![]() Grab a Mediterranean-take on the Monte Cristo with hand-carved ham, sautéed Swiss chard, pepperoncini and feta cheese on olive-and-roasted red pepper-crusted bread. The French Dip Meatball boasts Balinese inspired meatballs, creamy potato aioli, caramelized onions, melted gruyere cheese and au jus. On the sandwich front, there’s Bahn Mi, Watsons’ twist on a Vietnamese favorite with marinated sliced pork, pickled daikon, radish and carrot, English cucumbers, red jalapenos, cilantro and Cajun honey mustard sauce. Hungry for pizza? You can choose from New York-, Greek- or Cubano- or Tex-Mex-style. The menu is like a culinary United Nations, with different parts of the world represented. Located at 2193 Babcock Blvd., in the former Mediterrano space, the BYOB eatery features fresh, made-to-order dishes that nourish the body and soul. Watson hopes to replicate that sense of community and caring at Chef’s Table, his new restaurant opening this month in Ross Township. “I realized that the best times of my life were spent over food.” “It made us closer,” says the Erie native. Growing up, he shadowed her in the kitchen of their local community center, where she prepared meals for friends and neighbors. In the future, new insight into the cause of these conditions will aid in the development of other new approaches to therapy.Chef Kevin Watson is still tied to his grandmother’s apron strings. If this medication is proven effective in the treatment of Graves' ophthalmopathy, it will likely become a mainstay of therapy for this difficult-to-treat condition. Bahn's research into the causes of GO and Graves' hyperthyroidism has led to a clinical trial of rituximab as a new therapy for GO. In the future, clinical trials will be performed to determine whether these small molecules might be used as therapy for Graves' hyperthyroidism and Graves' ophthalmopathy.ĭr. This turns off the receptor and prevents TSHR autoantibodies from affecting these cells. Bahn's laboratory team is studying a novel small molecule that attaches to the TSHR receptor on thyroid cells and also on fibroblasts from behind the eye. ![]() ![]() What new therapies are being developed to treat Graves' hyperthyroidism and GO? Dr.The changes in the tissues behind the eye result in the clinical features of GO including forward protrusion of the eyeball, enlargement of the eye muscles, and swelling of the eyelids and tissues. These same antibodies target TSHR on fibroblasts behind the eye and cause them to turn into fat cells and produce hyaluronic acid, a substance found in abundance in the orbits of patients with GO. ![]() These antibodies attach to this receptor found on thyroid cells and stimulate the cells to secrete too much thyroid hormone, a condition called hyperthyroidism. What causes GO, the eye condition found in patients with Graves' disease? Antibodies targeting the TSHR are found in the blood of patients with Graves' disease and GO.Bahn's research is funded by the National Institutes of Health and Mayo Clinic. Studies are under way to understand interactions between these cells and antibodies that target the thyroid-stimulating hormone receptor (TSHR) found on these cells.ĭr. Her team is studying the unique features of these cells that render them particularly susceptible to autoimmune attack. Bahn's laboratory is interested in the mechanisms and consequences of immune system activation of fibroblasts from behind the eye, the target cells involved in GO. The long-term goal of her laboratory team is to develop effective new therapies for the treatment and prevention of these conditions.ĭr. Bahn, M.D., studies the causes of Graves' ophthalmopathy (GO), Graves' hyperthyroidism and other autoimmune thyroid diseases.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |